NCT01253473 - Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

January 31, 2016

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Budesonide

Inhaled budesonide twice daily plus inhaled ipratropium/albuterol combination four times daily and every 4 hours as needed

DRUG

budesonide/formoterol

Inhaled budesonide/formoterol (160/4.5 mcg Symbicort®) 2 puffs twice daily plus inhaled ipratropium/albuterol (Combivent®) 1 puff four times daily

DRUG

Ipratropium/albuterol

Inhaled ipratropium/albuterol combination 2 puffs four times daily

Trial Locations (7)

Temple University Medical Center, Philadelphia

University of Alabama Birmingham Medical Center, Birmingham

University of Iowa, Iowa City

National Jewish Health, Denver

Harbor UCLA Medical Center, Torrance

Brigham and Women's Hospital, Boston

Reliant Medical Group, Worcester